{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:44:27Z","timestamp":1791927867359,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semnephrol.2026.151688","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:51:51Z","timestamp":1772473911000},"page":"151688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?"],"prefix":"10.1016","volume":"46","author":[{"given":"Matthew R.","family":"Weir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0001","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1172\/JCI112013","article-title":"Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass","volume":"76","author":"Anderson","year":"1985","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0002","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0003","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151688_bib0004","first-page":"F85","article-title":"Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation","volume":"241","author":"Hostetter","year":"1981","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151688_bib0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.RES.37.1.101","article-title":"Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat","volume":"37","author":"Myers","year":"1975","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151688_bib0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"issue":"20","key":"10.1016\/j.semnephrol.2026.151688_bib0007","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"9176","key":"10.1016\/j.semnephrol.2026.151688_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"9069","key":"10.1016\/j.semnephrol.2026.151688_bib0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151688_bib0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151688_bib0012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151688_bib0013","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"suppl 20","key":"10.1016\/j.semnephrol.2026.151688_bib0014","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.37765\/ajmc.2021.88806","article-title":"ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease","volume":"27","author":"Fried","year":"2021","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semnephrol.2026.151688_bib0015","unstructured":"US Department of Health and Human Services. Increase the proportion of adults with diabetes and chronic kidney disease who get ACE inhibitors or ARBs\u2014CKD\u201105.https:\/\/odphp.health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/chronic-kidney-disease\/increase-proportion-adults-diabetes-and-chronic-kidney-disease-who-get-ace-inhibitors-or-arbs-ckd-05\/data. Accessed September 1, 2025"},{"issue":"4S","key":"10.1016\/j.semnephrol.2026.151688_bib0016","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"19","key":"10.1016\/j.semnephrol.2026.151688_bib0017","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2026.151688_bib0018","first-page":"S20","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.semnephrol.2026.151688_bib0019","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.3390\/jcm12186105","article-title":"Heart failure in patients with chronic kidney disease","volume":"12","author":"Xanthopoulos","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.semnephrol.2026.151688_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1523-1755.2004.09201.x","article-title":"Albuminuria, not only a cardiovascular\/renal risk marker, but also a target for treatment?","volume":"92","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151688_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2026.151688_bib0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151688_bib0023","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"issue":"suppl 3","key":"10.1016\/j.semnephrol.2026.151688_bib0024","doi-asserted-by":"crossref","first-page":"iii12","DOI":"10.1093\/ndt\/gfz231","article-title":"Hyperkalemia in patients with chronic renal failure","volume":"34","author":"Seliger","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2026.151688_bib0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0026","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151688_bib0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.semnephrol.2026.151688_bib0028","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151688_bib0029","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151688_bib0030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2026.151688_bib0031","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.semnephrol.2026.151688_bib0032","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151688_bib0033","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0034","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151688_bib0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2215\/CJN.0000000662","article-title":"Clinical implications of slope of GFR in clinical trials of CKD progression","volume":"20","author":"Greene","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.semnephrol.2026.151688_bib0036","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.118.038771","article-title":"Cardiovascular safety trials for all new diabetes mellitus drugs?","volume":"139","author":"Low Wang","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151688_bib0037","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151688_bib0038","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2026.151688_bib0039","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2026.151688_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151688_bib0041","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2026.151688_bib0042","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0043","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0044","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mayocp.2024.08.028","article-title":"Excessive initial renal function decline following sodium-glucose cotransporter-2 inhibitor treatment predicts major adverse cardiorenal outcomes","volume":"100","author":"Chen","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151688_bib0045","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ckj\/sfaa133","article-title":"Effects of canagliflozin on serum potassium in the Canagliflozin Cardiovascular Assessment Study (CANVAS) program","volume":"14","author":"Weir","year":"2021","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0046","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jdiacomp.2016.05.008","article-title":"Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney","volume":"30","author":"Palmer","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151688_bib0047","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2025.0686","article-title":"SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors","volume":"185","author":"Wing","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semnephrol.2026.151688_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors\u2014perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"20","key":"10.1016\/j.semnephrol.2026.151688_bib0049","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2019.09.022","article-title":"Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week","volume":"74","author":"Cherney","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.semnephrol.2026.151688_bib0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.semnephrol.2026.151688_bib0051","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151688_bib0052","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2026.151688_bib0053","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"issue":"23","key":"10.1016\/j.semnephrol.2026.151688_bib0054","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151688_bib0055","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0056","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151688_bib0057","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.semnephrol.2026.151688_bib0058","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2026.151688_bib0059","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.123.067620","article-title":"Mineralocorticoid receptor antagonism prevents aortic plaque progression and reduces left ventricular mass and fibrosis in patients with type 2 diabetes and chronic kidney disease: the MAGMA trial","volume":"150","author":"Rajagopalan","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151688_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/gfaf083","article-title":"Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure","volume":"41","author":"Bonifant","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2026.151688_bib0061","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151688_bib0062","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151688_bib0063","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151688_bib0064","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.semnephrol.2026.151688_bib0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.ackd.2021.06.001","article-title":"Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists","volume":"28","author":"Tommerdahl","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0066","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151688_bib0067","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:45:14Z","timestamp":1791924314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929526000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":67,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0270929526000240"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151688","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151688"}}